Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of beloranib in obese subjects with Prader-Willi syndrome
2015-000660-33Phase 3Terminated
- Sponsor
- Zafgen, Inc.
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Prader-Willi syndrome (PWS) and obesity comparing Beloranib with Placebo (2 arms). Started Aug 2015; status: terminated.
02
Drugs
beloranib
03
Conditions
Prader-Willi syndrome (PWS)obesity
Beyond the preview
Go deeper on 2015-000660-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000660-33.